Navigation Links
AIDS drug GS 9137 Shows Promise

The manufacturer of the experimental AIDS drug GS 9137 Gilead Sciences Inc. has revealed that the results of the drug experiments were successful, as lower levels of HIV were noticed in the case of those who were taking the treatment. // The experiment was conducted over a period of 10 days on 40 patients.

The negative side effects were also not seen to be of a serious nature. This new therapy is of the integrase inhibitors class which contributes towards preventing the virus from replicating itself. The new drug targets a weak point of the HIV which does not change its shape and evade treatment. The HIV's integrase comes under attack by the new drug which enables the merging of the virus with the human DNA.

The drug appears to be effective even in the case of patients whose virus has attained immunity to other medicines. An FDA approval for the drug will be sought by Merck in the year 2007.
'"/>




Page: 1

Related medicine news :

1. Experimental treatment for Ebola Virus Shows promising results in mice
2. New Prostate Cancer Vaccine Shows Promise
3. Ebola Treatment Shows Promise
4. New Drug Shows Significant Improvement In HIV-related Heart Condition
5. Greek Study Shows Living In The Hills May Be Healthier
6. Research Shows Carbon Monoxide Prevents Inflammations
7. Latest Research Shows That Multivitamins Might Not Prevent Infections In All Elderly
8. Novartis MS Drug Shows Promising Results
9. MRI Shows Emotional Changes During Menstrual Cycle
10. Bronchiolo-alveolar Carcinoma Shows Sonographic Pattern Of Pneumonia
11. Teenager Shows Signs Of Recovery after Receiving Massive Dose of Radiation
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: AIDS drug Shows Promise

(Date:3/31/2015)... In conjunction with the Asbestos Awareness ... Mesothelioma Applied Research Foundation (Meso Foundation) announced the ... its existing work in mesothelioma research, education, support, ... Meso Foundation’s mission, we want to eliminate harmful ... asbestos, including mesothelioma,” said the Meso Foundation’s executive ...
(Date:3/31/2015)... Karen A. Daley, Ph.D. will address graduates of ... Commencement ceremony on May 9, 2015 and will receive ... her eminent career as a nurse, public health advocate, ... senior staff nurse at Brigham and Women’s Hospital in ... including President of the American Nurses Association in which ...
(Date:3/31/2015)... Many people, including the ones with physical challenges, ... are only for able-bodied participants. , A new ... to change that thinking. , The program, part ... Sports Expo on Saturday, April 11 (10 a.m. to ... , The event will showcase a wide variety ...
(Date:3/31/2015)... OnChip Devices , a world leader in Integrated ... chip targeted towards low voltage LED applications. Adding to its ... for protecting circuits by suppressing voltage higher than 3.0 Volts. ... up to 350W and 20A, providing protection of 8kV when ... These diodes do not exhibit any device degradation when compared ...
(Date:3/31/2015)... The Walk a Mile Project, as part ... just kicked off their 3rd research sequence. The new ... Substantial Equivalence was and is a massive component of ... at Change The World Films. “We started our research ... even entered our food supply, just to get a bird's ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Research Organization Announces New Prevention Program 2Health News:Mesothelioma Research Organization Announces New Prevention Program 3Health News:Rivier University to recognize nurse leader, educator and safety advocate at 80th Commencement on May 9th 2Health News:Rivier University to recognize nurse leader, educator and safety advocate at 80th Commencement on May 9th 3Health News:Memorial Healthcare System's Adaptive Sports Expo Encourages Physically Challenged To Go Beyond Perceived Limitations 2Health News:OnChip Introduces Low Voltage Diodes for High-Brightness LED Protection 2Health News:The Walk a Mile Project Launches New Research Sequence on Substantial Equivalence of GMOs 2
... Leading Urology Annual MeetingSUNNYVALE, Calif., April 23 Accuray ... in the field of radiosurgery, announced today that more ... date worldwide using the CyberKnife(R) Robotic Radiosurgery System. In ... approximately 400 prostate cancer patients were treated. The company ...
... LOUIS, April 23 Sigma-Aldrich Corporation, a leading Life Science ... diluted EPS grew by 6% to $0.68 from $0.64 in ... of 2009 were $519 million, a decline of 9% from ... first quarter sales grew organically by 1% from a year ...
... BEACH, Fla., April 23 The Cosmetic Bootcamp LLC announces ... in Aspen, Colorado. Leading skin care experts from dermatology and ... event was made possible by a generous grant from Johnson ... in ethnic skincare. Among the faculty attending this meeting will ...
... PARK, N.J., April 23 OTC Perspectives - a ... company DTC Perspectives Inc. - has announced the finalists ... leading healthcare brands named as finalists are Aleve, Benadryl, ... winners of OTC National Advertising Awards will be announced ...
... Conn., April 23 CuraGen Corporation (Nasdaq: ... first quarter of 2009. During the three month period ... and investments for operations and repurchased $4.8 million of debt ... million of cash and investments. As of March ...
... 23 April: The first identification of GP130 ... today at EASL 2009, the Annual Meeting of ... Disease in Copenhagen, Denmark. , Identification of recurrent ... reveals a new pathway of tumourigenesis in humans, ...
Cached Medicine News:Health News:CyberKnife Radiosurgery Used to Treat More Than 3,000 Prostate Cancer Patients Worldwide 2Health News:CyberKnife Radiosurgery Used to Treat More Than 3,000 Prostate Cancer Patients Worldwide 3Health News:CyberKnife Radiosurgery Used to Treat More Than 3,000 Prostate Cancer Patients Worldwide 4Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 2Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 3Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 4Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 5Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 6Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 7Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 8Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 9Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 10Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 11Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 12Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 13Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 14Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 15Health News:J&J, Schering-Plough, Novartis, Bayer vie for Top Honors at the Premier OTC / Healthcare Ad Awards 2Health News:CuraGen Reports First Quarter 2009 Financial Results 2Health News:CuraGen Reports First Quarter 2009 Financial Results 3Health News:CuraGen Reports First Quarter 2009 Financial Results 4Health News:CuraGen Reports First Quarter 2009 Financial Results 5Health News:New oncogene gives valuable insight into hepatocellular tumors in humans 2
(Date:3/31/2015)... , March 31, 2015  CVS Health (NYSE: ... into new clinical affiliations with Rush University Medical ... and Tucson Medical Center in Tucson, ... Arizona Connected Care. These affiliations will help enhance ... patients. Through these clinical affiliations, CVS Health will ...
(Date:3/31/2015)... , March 31, 2015  Oxis International, Inc. (OXIS) ... development and commercialization, announced today Oxis CEO Tony ... of Oxis common shares on the Euronext exchange. Oxis ... the symbol OXIS.   Oxis Chairman and ... to move forward with its strategies launched in 2014 ...
(Date:3/31/2015)... MIAMI , March 31, 2015 ... TALOS™, today announced a strategic partnership with ... solutions for clinical research in life sciences. Offering ... global CRO has deployed Medidata,s electronic data capture ... support Biorasi,s Phase I through IV global clinical ...
Breaking Medicine Technology:CVS Health Announces New Clinical Affiliations with Leading Medical Centers in Arizona and Illinois 2CVS Health Announces New Clinical Affiliations with Leading Medical Centers in Arizona and Illinois 3Oxis International Inc. Announces Request for Euronext Trading Suspension 2Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 2Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 3Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 4
... 15, 2012 ViroPharma Incorporated,s (Nasdaq: VPHM ) ... expected to be released on Tuesday, February 28, 2012 before ... company will host a conference call and live audio webcast ... the conference call, ViroPharma management will discuss the 2011 fourth ...
... is a compelling example of the life-changing importance of organ ... decision to donate his wife,s organs in hopes of helping ... when he received a donor heart transplant after 120 days ... . (Photo: http://photos.prnewswire.com/prnh/20120215/LA53807 ) ...
Cached Medicine Technology:ViroPharma to Release 2011 Fourth Quarter and Full Year Financial Results on February 28, 2012 2Total Artificial Heart Patient Receives Donor Heart 15 Years After Decision to Donate Wife's Organs 2Total Artificial Heart Patient Receives Donor Heart 15 Years After Decision to Donate Wife's Organs 3Total Artificial Heart Patient Receives Donor Heart 15 Years After Decision to Donate Wife's Organs 4
... vascular closure device quickly seals ... procedures, allowing for early ambulation ... creates a mechanical seal by ... bio-absorbable anchor and collagen sponge, ...
Terumo's Optitorque offers superior torque and precision control. It's patient-friendly, high torque design makes it the catheter of choice for demanding angiography....
Jography angiographic catheter has a new material combination, a patented angled weld, a flat wire braid design with a XXL lumen. It also has an atraumatic soft tip....
Femoral selective catheter. Catheter material used is polyurethane (TRICOR). Guidewire campatibility is 0.038". Packaging 5/Box....
Medicine Products: